Radical Hypofractionated Radiotherapy for Localized Prostate Cancer

The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer. Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects. Accumulating evidence has proven the safety and feasibility of hypofractionated radiotherapy for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of hypofractionated radiotherapy is still on its way.

Trial Details

NCT ID
NCT06325774
Phase
NA
Sponsor
Changhai Hospital
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Hypofractionated radiation therapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age: ≥18 years old;
  • European Cooperative Oncology Group score(ECOG):≤ 2;
  • Patients with pathologically diagnosed prostate cancer;
  • Clinical stage was cTanyN0M0 any Gleason / ISUP group;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →